





Closed Trials – status update

# ENGOT-cx1 Randomized Phase II of paclitaxel-carboplatin +/- Nintedanib



\* Protocol v5.0 or above

Trial setting: Cervix/ primary stage IVB, recurrent

Sponsor(s): BGOG

Planned No. of patients: 120

Current accrual: 120

FPI: Mar 2014 ; LPI: **5 October 2018**

Primary endpoint: PFS      Secondary endpoint: OS, toxicity, safety, QOL and RR



# Closed Trials – status update

## ENGOT-cx1 Randomized Phase II of paclitaxel-carboplatin +/- Nintedanib

